Tags

Type your tag names separated by a space and hit enter

Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.
Bone Marrow Transplant. 1989 Jul; 4(4):367-71.BM

Abstract

Thirty-eight patients with haematological malignancies were treated with bone marrow transplantation using histocompatible immunotoxin T cell-depleted marrow siblings. All patients received conventional postgraft immunosuppression (methotrexate and/or cyclosporin A). Donor bone marrow was treated ex vivo with T101 Fab fragment coupled to ricin A-chain (T101 Fab-RTA) at a concentration of 10(-8) M of A-chain in association with NH4Cl (2 x 10(-2) M) in pH adjusted (7.8) incubation medium. A median cytoreduction of 99.5% (91-99.5) was obtained. The median of follow-up was 300 days. Only three patients developed grade II acute graft-versus-host disease (GVHD) (actuarial rate of acute GVHD: 9.1%). No chronic GVHD occurred. All patients but one engrafted. Six out of the 37 patients developed a documented bone marrow rejection (actuarial rate of graft failure: 18%). Ten patients relapsed (actuarial rate of relapse: 36.9%). These findings demonstrate that treatment of donor marrow with T101 Fab-RTA in association with NH4Cl at critical pH value can achieve a high level of mature T cell depletion and greatly reduce the incidence of bone marrow rejection and relapse after T cell-depleted allogeneic bone marrow transplantation.

Authors+Show Affiliations

Sanofi Recherche, Montpellier, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2789084

Citation

Laurent, G, et al. "Donor Bone Marrow Treatment With T101 Fab Fragment-ricin A-chain Immunotoxin Prevents Graft-versus-host Disease." Bone Marrow Transplantation, vol. 4, no. 4, 1989, pp. 367-71.
Laurent G, Maraninchi D, Gluckman E, et al. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. Bone Marrow Transplant. 1989;4(4):367-71.
Laurent, G., Maraninchi, D., Gluckman, E., Vernant, J. P., Derocq, J. M., Gaspard, M. H., Rio, B., Michalet, M., Reiffers, J., & Dreyfus, F. (1989). Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. Bone Marrow Transplantation, 4(4), 367-71.
Laurent G, et al. Donor Bone Marrow Treatment With T101 Fab Fragment-ricin A-chain Immunotoxin Prevents Graft-versus-host Disease. Bone Marrow Transplant. 1989;4(4):367-71. PubMed PMID: 2789084.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. A1 - Laurent,G, AU - Maraninchi,D, AU - Gluckman,E, AU - Vernant,J P, AU - Derocq,J M, AU - Gaspard,M H, AU - Rio,B, AU - Michalet,M, AU - Reiffers,J, AU - Dreyfus,F, PY - 1989/7/1/pubmed PY - 1989/7/1/medline PY - 1989/7/1/entrez SP - 367 EP - 71 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 4 IS - 4 N2 - Thirty-eight patients with haematological malignancies were treated with bone marrow transplantation using histocompatible immunotoxin T cell-depleted marrow siblings. All patients received conventional postgraft immunosuppression (methotrexate and/or cyclosporin A). Donor bone marrow was treated ex vivo with T101 Fab fragment coupled to ricin A-chain (T101 Fab-RTA) at a concentration of 10(-8) M of A-chain in association with NH4Cl (2 x 10(-2) M) in pH adjusted (7.8) incubation medium. A median cytoreduction of 99.5% (91-99.5) was obtained. The median of follow-up was 300 days. Only three patients developed grade II acute graft-versus-host disease (GVHD) (actuarial rate of acute GVHD: 9.1%). No chronic GVHD occurred. All patients but one engrafted. Six out of the 37 patients developed a documented bone marrow rejection (actuarial rate of graft failure: 18%). Ten patients relapsed (actuarial rate of relapse: 36.9%). These findings demonstrate that treatment of donor marrow with T101 Fab-RTA in association with NH4Cl at critical pH value can achieve a high level of mature T cell depletion and greatly reduce the incidence of bone marrow rejection and relapse after T cell-depleted allogeneic bone marrow transplantation. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/2789084/Donor_bone_marrow_treatment_with_T101_Fab_fragment_ricin_A_chain_immunotoxin_prevents_graft_versus_host_disease_ L2 - https://www.lens.org/lens/search/patent/list?q=citation_id:2789084 DB - PRIME DP - Unbound Medicine ER -